Introduction
Diffuse large B-cell lymphoma (DLCBL) is the most frequent form of lymphoid cancer, accounting for 30-35% of all nodal lymphomas. 1 Based on gene expression profiling (GEP), three distinct subtypes of DLBCL have been identified, namely the germinal center B-cell (GCB), activated B-cell (ABC) and primary mediastinal B-cell lymphoma subtypes. 2 The ABC subtype of DLBCL is characterized by adverse prognosis and constitutive activation of the transcription factor NF-κB. 3 This is thought to be the consequence of somatic mutations in the genes encoding the B-cell receptor (BCR)-associated CD79A and CD79B chains, 4 or the BCR signal transducer CARMA1 (also known as CARD11), 5 and polymorphisms in RNF31 (also known as HOIP), 6 which result in constitutive BCR signaling. These can be present alone or in combination with activating mutations in genes encoding the Toll like receptor (TLR)
downstream signaling protein MyD88 7 and inactivation and/or deletion of the gene encoding A20, a negative regulator of the NF-κB pathway. 8 As a consequence of these mutations, ABC DLBCL have a constitutive activation of NF-κB via BCRand/or TLR-signaling pathways, whose natural physiological role is to promote B-cell proliferation and survival. Recent studies have provided some insight into how the BCR and the TLR signaling pathways activate gene transcription via the AP-1 pathway. 18 BCR signaling depends on the CARMA1-BCL10-MALT1 (CBM) complex, while TLR signaling depends on the adaptor protein MyD88 and the kinases IRAK1 and IRAK4. The ubiquitin ligase TRAF6 and the Ser/Thr kinase TAK1 are downstream targets of both, BCR/CBM-and TLR/MyD88/IRAK-dependent signals. TAK1 has been reported to act as an upstream regulator of the c-Jun N-terminal kinase, JNK, [19] [20] [21] [22] it is thus generally assumed that BCR-and TLR-induced JNK activation is crucial for AP-1 activation. However, the exact role of JNK in the activation of individual AP-1 family heterodimers in lymphocytes remains incompletely understood, and whether JNK is strictly required for AP-1 activation in lymphocytes remains controversial. [23] [24] [25] [26] Another particular difficulty in studying the role of AP-1 transcription factors is the fact that the AP-1 family comprises more than 20 members that can form numerous different heterodimers with partially redundant functions and highly diverse mechanisms of regulation. 11 Therefore, little is currently known about the exact composition and relevance of AP-1 complexes in activated lymphocytes and the development of ABC DLBCL.
Here, we show that cell lines derived from ABC DLBCL are characterized by constitutive upregulation of c-Jun, JunB and ATF3, which was mediated by CARMA1 and MyD88. Jun members formed complexes with ATF2 or ATF7
(complexes of type I), or with ATF3 (complexes of type II). Inhibition of these complexes by a dominant negative approach impaired the viability of most ABC DLBCL cell lines. Amongst the different members of the complexes, ATF3, ATF2
and c-Jun were the main drivers of cellular survival. Interestingly, ATF3, but not ATF2 or ATF7, was exclusively expressed in cell lines derived from the ABC subtype of DLBCL, and immuno-histochemical analysis of biopsies of DLBCL patients confirmed preferential strong and nuclear ATF3 staining in samples from patients with nodal lymphoma of the non-GC or ABC subtype of DLBCL.
Collectively, these findings identify the activation of specific AP-1 complexes as a hallmark of ABC DLBCL.
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Methods
Cellular transfection and transduction
Lentiviral transduction and viability assays have been described. 28 Expression of AFos in DLBCL lines was achieved by retroviral transduction as described previously 29 . The transduced cells were monitored for live GFP + cells by flow cytometry as described.
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Cell culture, cell stimulation and reporter assays
Jurkat cells and DLBCL cell lines BJAB, SUDHL-4, SUDHL-6, HT, HBL-1, OCILy3, OCI-Ly10 and TMD8 were cultured as described. 30 For stimulation of Jurkat T cells, a mixture of PMA (phorbol 12-myristate 13-acetate; 10 ng/ml; Alexis) and ionomycin (1 μ M; Calbiochem) was used. In some experiments, cells were preincubated with 1 μ M of the JNK inhibitor SP600125 (Calbiochem), 1 μ M of TAK1 inhibitor 5Z7 (Sigma), PKC inhibitors (500 nM bisindoleylmaleimide VIII acetate (Alexis) or 1 μ M of Gö6976 (Calbiochem)) or with corresponding volumes of solvent for the indicated times at 37°C. IL-2 luciferase assays were performed as described.
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Cell lysis, immunoprecipitation and Western blot analysis
Cells were lysed in RIPA buffer containing 50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl and 1mM EDTA, or in lysis buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, protease inhibitors (Complete; Roche) and phosphatase inhibitors (NaF, Na 4 P 2 O 7 and Na 3 VO 4 ). In some experiments, lysates were incubated with or without 0.5 mM BS3
(Thermo Scientific) for 1h at 4°C. Immunoprecipitation, sample analysis by high resolution SDS-PAGE and immunoblot were performed as described.
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Patient populations
The construction of the tissue microarray (TMA) with samples from de novo previously untreated DLBCL patients classified by the Hans algorithm 31 has been described elsewhere. 32 Of the original cohort of 109 patients, sufficient tumor tissue for additional immunohistochemical analyses was available from 70 patients. The local ethics committee approved this retrospective analysis (KEK 160/14). A second 7 cohort of DLBCL patients consisted of a GEP-characterized subset of a patient cohort already published. 29 The study of this cohort was approved by the ethics committee of Northwestern and Central Switzerland (EKNZ 2014-252).
Immunohistochemistry for ATF3
Immunohistochemical staining of the ATF3 protein was performed on the TMA slides using an automated immunostainer (Leica BOND-III, Leica Biosystems). As a pretreatment for antigen retrieval, the TMA section was placed in epitope retrieval solution (Tris buffer for 30 min at 95°C). Subsequently, the TMA was incubated at room temperature with rabbit anti-human ATF3 antibody (sc-188, Santa Cruz) at a working concentration of 1:50 for 30 min. Antigen detection was performed using a commercial detection kit (Bond Polymer Refine Detection) with diaminobenzidin as the chromogen.
Immunohistochemical scoring
For assessment of ATF3 expression, the stained TMA slides were scanned with Aperio (Vista, USA) and evaluated at 40x magnification. The staining intensity was stratified from 0 -2, where 0 (designated "weak") = negative or weak staining in <10% of neoplastic cells, 1 (designated "intermediate") = weak or moderate staining in >10% neoplastic cells and 2 (designated "strong") = strong staining in >10% of neoplastic cells. Staining was further categorized by its pattern as partially or predominantly nuclear (N) or cytoplasmic (C). Staining intensity was semiquantitative and used internal samples as reference points.
Plasmids, antibodies, mass spectrometry and fluorescence microscopy
Detailed information about plasmids, antibodies, mass spectrometry and fluorescence microscopy can be found in the supplemental material.
Statistical analysis
Two-tailed Student's t-test was used for statistical analysis; P values of 0.05 or less were considered statistically significant. Table 1 ), suggesting that type I complexes contain both, c-Jun/ATF2
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and c-Jun/ATF7 heterodimers. ATF2 and ATF7 expression levels were similar in all
ABC and GCB cell lines tested, with the exception of HBL-1 cells, which had slightly higher ATF2 expression levels ( Figure 2C ). Cross-linking of lysates using BS3
revealed that ATF2 and ATF7 formed high molecular weight complexes in both GCB and ABC DLBCL cell lines, and that these complexes corresponded in molecular weight to type I complexes ( Figure 2D 
ATF3 is specifically upregulated and forms type II complexes with Jun family members in ABC DLBCL cell lines
Protein components present in type II complexes were not sufficiently abundant to be identified by mass spectrometry. However, based on the relative molecular weight of the chemically cross-linked type II complexes, we hypothesized that these may correspond to lower molecular weight members of the ATF subfamily, such as ATF3 and JDP2. In line with this idea, we found that ATF3 was specifically expressed in cell lines derived from ABC, but not from GCB DLBCLs ( Figure 3A) . In contrast, the unconventional ATF family member JDP2, which acts as a repressor of ATF2 and ATF3 function, 40,41 was less abundant in three out of four ABC as compared to GCB DLBCL cell lines. JDP2 has been shown to be targeted for proteasomal degradation upon its phosphorylation. 42 Indeed, all ABC DLBCL cell lines were characterized by the presence of an additional slower-migrating, phosphatase-sensitive isoform of JDP2 ( Figure 3A , and data not shown), suggesting that JDP2 is constitutively phosphorylated and targeted for proteasomal degradation in ABC DLBCL cell lines.
As for c-Jun and JunB, the expression of ATF3 was strongly reduced upon silencing of CARMA1, MALT1, IRAK1 and MyD88 ( Figure 3B ). Upon treatment with the chemical cross-linker BS3, ATF3 shifted towards a higher molecular weight complex that corresponded in size to the previously described type II complexes ( Figure 3C ). Moreover, ATF3 could easily be co-immunoprecipitated with c-Jun, JunB and JunD in lysates of ABC DLBCL cell lines ( Figure 3D ). Collectively, these findings suggest that the AP-1 family member ATF3 is selectively expressed in cell lines derived from ABC DLBCL, and forms constitutive complexes with c-Jun, JunB and JunD (type II complexes, Figure 3E ) in these cells.
Inhibition of Jun family members by A-Fos impairs the viability of cell lines derived from ABC DLBCL.
To explore the role of Jun/ATF-type dimers in ABC DLBCL, we made use of a previously described dominant negative A-Fos construct. for scoring details, see materials and methods) and the preferential localisation (cytoplasmic (C), exclusively or partially nuclear (N)). First, we analysed a cohort of 70 DLBCL samples, which were classified into GCB and non-GC DLBCL according to the Hans algorithm, 32 and were derived from 28 nodal and 42 extranodal tumors.
These IHC analyses showed various expression patterns, which differed in intensity and staining pattern, examples of these are shown in Figure 5C . When scoring ATF3 expression intensities and patterns in the combined samples, we observed a small tendency towards higher and nuclear expression in non-GC versus GCB samples (supplemental Figure 3) . This tendency was striking in samples obtained from nodal tumors ( Figure 5D ). only one GCB DLBCL sample (Fig. 5E) . In the majority of non-GC DLBCL samples (14 out of 19), or GEP-identified ABC DLBCL samples (6 out of 9), the ATF3 staining was partially or predominantly nuclear. Collectively, these data identify high and preferentially nuclear protein expression of ATF3 as a hallmark of human non-GC/ABC DLBCL.
Discussion
In the present study, we demonstrated a new and essential role for the activation of 
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Plasmids
The FLAG-A-Fos sequence was obtained from Addgene (Plasmid 33353) and subcloned into the retroviral vector pMSCV-IRES-GFP. 27 The following lentiviral vectors (pLKO.1) were used for ATF2, ATF7, ATF3, c-Jun, IRAK1 and MyD88 silencing in DLBCL cell lines: ATF2 shRNA (TRCN0000229648), and ATF3 (TRCN0000013568, TRCN0000013571, TRCN0000013572), ATF7 (TRCN0000017116), c-Jun shRNA (TRCN0000039590), IRAK1 shRNA (TRCN0000000544) and MyD88 (TRCN0000008024). For silencing of MALT1 and CARMA1, cells were transduced with a lentiviral vector (pAB286.1, a kind gift of R. Iggo, Bordeaux, France) containing short hairpin RNA sequences specific for CARMA1 (5'-GCTATGATTTCTCTTGCAT-3') or MALT1 (5'-GTCACAGAATTGAGTGATTTC-3').
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Antibodies
Antibodies against Tubulin (B-5-1-2), FLAG (M2) and P-ERK (MAPK-YT) were from Sigma; c-Jun (60A8), JunB (C37F9), JunD (D17G2), ATF2 (20F1), P-p38 (D3F9), JNK and P-IκBα (5A5) antibodies were from Cell Signaling, and ATF3 (C-19), MyD88 (E-11), IRAK1 (H-273) and P-c-Jun (KM-1) antibodies were from Santa Cruz Biotechnology. Other antibodies used were specific for CARMA1 (AL220; Alexis), P-JNK (Invitrogen), ATF7 (NBP1-30071, Novus Biologicals) and JDP2 (Abcam Ab40916). Affinity-purified anti-MALT1 has been reported. 27, 28 Horseradish peroxidase-coupled goat anti-mouse (115-035-146) and anti-rabbit (111-035-144) were from Jackson ImmunoResearch.
Analysis of c-Jun binding partners by mass spectrometry
Large-scale immunoprecipitation with anti-c-Jun coupled to protein G Sepharose beads or protein G Sepharose beads was performed on cross-linked HBL-1 lysates, followed by SDS-PAGE and staining with colloidal Coomassie (Invitrogen). The bands corresponding to complexes of type I and II were excised. Proteins were in-gel reduced with DTT, alkylated with iodoacetamide and digested with sequencing-grade trypsin. Extracted peptides were analyzed by nanoflow liquid chromatographytandem mass spectrometry on a LTQ-Velos PRO orbitrap mass spectrometer (Thermo Fisher Scientific). Tandem mass spectra of peptides were searched with MASCOT (Matrix Science, London) against the UniProtKB protein sequence database. Identifications were filtered with Scaffold (Proteome Sciences, Portland, Oregon) to have a minimum of 95% probability and two peptides. The ten most abundant proteins in the 40-60 and 100-150 kD mass ranges that were identified by this approach are listed in the supplemental Table 1 .
Immunofluorescence Microscopy
Lymphoma cells were cytospinned for 6 min at 900 rpm to Superfrost®Plus microscope slides (Thermo Scientific). Slides were washed with PBS, the cells fixed with ice cold methanol for 30 min and permeabilized with 0.1 % Triton X-100 in PBS for 15 min. Nonspecific staining was blocked with 1 % BSA in PBS overnight at 4°C. Next, the slides were incubated with anti-ATF3 antibody (1:50) in 1 % BSA for 2 h at room temperature. Cells were washed with PBS and stained with labeled F(ab')2 antibody fragments for 1 h. After washing with PBS, DAPI-containing ProLong antifade kit (Molecular Probes) was mounted on dried slides to visualize DNA and protect the slides from bleaching. Fluorescence microscopy was performed using Carl Zeiss LSM 510 confocal microscopes and the images were analyzed by Carl Zeiss LSM or ZEN 2007 image software.
Cell viability assay 72 h after infection, transduced DLBCL cells were selected with puromycin (1 ug/ml) for 24 h, and silencing efficiency was determined by western blot. Cells were replated at the same concentration, and cell viability was assessed 5 days later using MTS (Promega, 400 µg/mL) and PMS (Sigma, 9 µg/mL), according to the manufacturer's instructions. Reduction of MTS to formazan was measured at 492 nm with Capture 96 Software on a LEDETECT 96 microplate spectrophotometer (Dynamica). 
